A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae | Zendy

Roberto DíezMartínez | Zendy; Héctor D. de Paz | Zendy; Esther GarcíaFernández | Zendy; Noemí Bustamante | Zendy; Chad W. Euler | Zendy; Vincent A. Fischetti | Zendy; Margarita Menéndez | Zendy; Pedro Garcı́a | Zendy

Open Access

A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae

Author(s) -

Roberto DíezMartínez,

Héctor D. de Paz,

Esther GarcíaFernández,

Noemí Bustamante,

Chad W. Euler,

Vincent A. Fischetti,

Margarita Menéndez,

Pedro Garcı́a

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv038

Subject(s) - lysin , microbiology and biotechnology , streptococcus pneumoniae , biofilm , bacteria , biology , lytic cycle , pneumococcal infections , population , bacteriophage , antibiotics , chemistry , virology , escherichia coli , medicine , biochemistry , gene , virus , genetics , environmental health

Streptococcus pneumoniae is becoming increasingly antibiotic resistant worldwide and new antimicrobials are urgently needed. Our aim was new chimeric phage endolysins, or lysins, with improved bactericidal activity by swapping the structural components of two pneumococcal phage lysozymes: Cpl-1 (the best lysin tested to date) and Cpl-7S.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research